Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Official title: A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2023-10-18
Completion Date
2031-07-27
Last Updated
2026-08-10
Healthy Volunteers
No
Interventions
BMS-986460
Specified dose on specified days.
Locations (15)
Stanford Cancer Center
Palo Alto, California, United States
Florida Cancer Specialists Sarasota Drug Development Unit
Sarasota, Florida, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke Cancer Institute
Durham, North Carolina, United States
Local Institution - 0006
San Antonio, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Local Institution - 0009
Toronto, Ontario, Canada
Local Institution - 0011
Montreal, Quebec, Canada
Local Institution - 0018
Bordeaux, Aquitaine, France
Centre Leon Berard
Lyon Cedex08, Auvergne-Rhône-Alpes, France
Institut Paoli-Calmettes
Marseille, Nan, France
Gustave Roussy
Villejuif, Val-de-Marne, France
Local Institution - 0017
Paris, France